Fmr LLC C4 Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 23,627 shares of CCCC stock, worth $132,547. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,627

Previous 37,288 36.64%

Holding current value

$132,547

Previous $304,000 64.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.05 - $8.1 $55,327 - $110,654	-13,661 Reduced 36.64%	23,627 $109,000
Q1 2024 May 13, 2024	SELL	$5.3 - $11.0 $1,441 - $2,992	-272 Reduced 0.72%	37,288 $304,000
Q4 2023 Feb 13, 2024	SELL	$1.18 - $6.03 $98,653 - $504,138	-83,605 Reduced 69.0%	37,560 $212,000
Q3 2023 Nov 13, 2023	BUY	$1.81 - $3.89 $120,180 - $258,288	66,398 Added 121.24%	121,165 $225,000
Q2 2023 Aug 11, 2023	SELL	$2.75 - $3.77 $921 - $1,262	-335 Reduced 0.61%	54,767 $150,000
Q1 2023 May 11, 2023	BUY	$3.1 - $9.02 $8,565 - $24,922	2,763 Added 5.28%	55,102 $173,000
Q4 2022 Feb 13, 2023	SELL	$5.42 - $10.24 $28,081 - $53,053	-5,181 Reduced 9.01%	52,339 $308,000
Q3 2022 Nov 10, 2022	BUY	$8.03 - $12.77 $451,366 - $717,801	56,210 Added 4290.84%	57,520 $504,000
Q2 2022 Aug 12, 2022	SELL	$5.06 - $26.46 $3.03 Million - $15.8 Million	-597,971 Reduced 99.78%	1,310 $10,000
Q1 2022 May 13, 2022	SELL	$19.99 - $33.23 $993,502 - $1.65 Million	-49,700 Reduced 7.66%	599,281 $14.5 Million
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $2.5 Million - $3.52 Million	69,700 Added 12.03%	648,981 $29 Million
Q2 2021 Aug 13, 2021	BUY	$30.39 - $42.18 $17.6 Million - $24.4 Million	579,281 New	579,281 $21.9 Million

Others Institutions Holding CCCC

# of Institutions

125

Shares Held

53.9M

Call Options Held

331K

Put Options Held

145K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $274M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account